Simon Heeke
The University of Texas MD Anderson Cancer Center · 184 works · 4,604 citations · h-index 30
Top works
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- Structure-based classification predicts drug response in EGFR-mutant NSCLC
- Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
- Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions
- Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
- Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
- Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
- Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
- Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights
- Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer
- Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
- A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
- Never Travel Alone: The Crosstalk of Circulating Tumor Cells and the Blood Microenvironment
- Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
- CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance
- Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients
- In-house Implementation of Tumor Mutational Burden Testing to Predict Durable Clinical Benefit in Non-small Cell Lung Cancer and Melanoma Patients
- Two Patients With Advanced-Stage Lung Adenocarcinoma With Radiologic Complete Response to Nivolumab Treatment Harboring an STK11/LKB1 Mutation
- Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
- Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology